Updated with guidance for 2009Gilead Sciences ( GILD) reported a 44% increase in adjusted second-quarter profits bolstered by strong HIV drug sales. The Foster City, Calif.-based biopharmaceutical firm reported net income of $571.4 million, or 61 cents a share, up from $434.8 million, or 49 cents a share in the year-ago quarter. On an adjusted basis, Gilead earned 69 cents a share in the June quarter, easily surpassing the consensus analyst estimate of 61 cents a share, according to Thomson Reuters. Total revenue in the quarter came in at $1.65 billion, up 29% from one year ago, topping Wall Street forecasts. Gilead business is dominated by sales of drugs used to treat patients with HIV and other viral-based diseases. Total antiviral sales (which includes HIV and hepatitis B) rose 26% to $1.41 billion in the quarter. Of note, sales of Atripla, a once-daily pill that combines three different HIV medicines including one from Bristol-Myers Squibb ( BMY), totaled $569.1 million, up 60% year over year, while sales of Truvada, another HIV combination pill, rose 18% to $608.1 million. Both Atripla and Truvada outperformed analyst forecasts. Outside of HIV, Gilead said sales of Ranexa totaled $36.1 million in the quarter, also ahead of expectations. Ranexa is a drug for chronic angina that was acquired when Gilead purchased CV Therapeutics earlier this year. Last week, Gilead and Johnson & Johnson ( JNJ) signed a partnership to develop a new single-pill treatment for HIV. Gilead raised 2009 guidance for total product sales to a range of $6.1 billion to $6.2 billion from the previous forecast of $5.9 billion to $6 billion. That's still below Street consensus of $6.3 billion. Ahead of its earnings announcement, Gilead shares closed Tuesday up 1% to $48.55.